Glycaemic effects of incretins in Type 1 diabetes mellitus
- 15 September 2004
- journal article
- review article
- Published by Elsevier in Regulatory Peptides
- Vol. 128 (2) , 149-157
- https://doi.org/10.1016/j.regpep.2004.06.003
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- What do we know about the secretion and degradation of incretin hormones?Regulatory Peptides, 2005
- Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patientsDiabetes Care, 1996
- Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)- (7-36) amide in type 2 (noninsulin-dependent) diabetic patientsJournal of Clinical Endocrinology & Metabolism, 1996
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Determinants of Clinical Remission in Recent-Onset IDDMDiabetes Care, 1993
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992
- Natural Course of Remission in IDDM During 1st yr After DiagnosisDiabetes Care, 1992
- Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporineDiabetes, 1991
- Immunosuppression in IDDM: Rationale, Risks, Benefits, and StrategiesDiabetes Care, 1990
- Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial GroupDiabetes, 1988